References
- Feldman C, Anderson R. Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections. F1000Res. 2020;9:338. doi: 10.12688/f1000research.22341.1.
- Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4(3):144–154. doi: 10.1016/S1473-3099(04)00938-7.
- Igarashi A, Ueyama M, Idehara K, et al. Burden of illness associated with pneumococcal infections in Japan - a targeted literature review. J Mark Access Health Policy. 2022;10(1):2010956.
- Gierke RW, A, Patricia, Kobayashi M. Pneumococcal disease: centers for disease control and prevention. 2021 [cited 2023 Feb 23]. Available from: https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pneumo.pdf.
- Yildirim I, Shea KM, Pelton SI. Pneumococcal disease in the era of pneumococcal conjugate vaccine. Infect Dis Clin North Am. 2015;29(4):679–697. doi: 10.1016/j.idc.2015.07.009.
- Schiess N, Groce NE, Dua T. The impact and burden of neurological sequelae following bacterial meningitis: a narrative review. Microorganisms. 2021;9(5):900. doi: 10.3390/microorganisms9050900.
- Myint TT, Madhava H, Balmer P, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30(2):127–151. doi: 10.1007/s12325-013-0007-6.
- Katsuta T, Moser CA, Feemster KA, et al. Comparison of immunization systems in Japan and the United States - What can be learned? Vaccine. 2020;38(46):7401–7408. doi: 10.1016/j.vaccine.2020.09.028.
- Japan Pediatric Society. Immunization schedule recommended by the Japanese pediatric society. 2020. [cited 2023 Jan 19]. Available from: https://www.jpeds.or.jp/modules/activity/index.php?content_id=138.
- Iwata S, Takata M, Morozumi M, et al. Drastic reduction in pneumococcal meningitis in children owing to the introduction of pneumococcal conjugate vaccines: longitudinal analysis from 2002 to 2016 in Japan. J Infect Chemother. 2021;27(4):604–612. doi: 10.1016/j.jiac.2020.11.019.
- Takeuchi N, Naito S, Ohkusu M, et al. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan. Epidemiol Infect. 2020;148:e91. doi: 10.1017/S0950268820000813.
- Ubukata K, Morozumi M, Sakuma M, et al. Etiology of acute otitis media and characterization of pneumococcal isolates after introduction of 13-Valent pneumococcal conjugate vaccine in japanese children. Pediatr Infect Dis J. 2018;37(6):598–604. doi: 10.1097/INF.0000000000001956.
- Ubukata K, Takata M, Morozumi M, et al. Effects of pneumococcal conjugate vaccine on genotypic penicillin resistance and serotype changes, Japan, 2010-2017. Emerg Infect Dis. 2018;24(11):2010–2020. doi: 10.3201/eid2411.180326.
- Suga S, Chang B, Asada K, et al. Nationwide population-based surveillance of invasive pneumococcal disease in japanese children: effects of the seven-valent pneumococcal conjugate vaccine. Vaccine. 2015;33(45):6054–6060. doi: 10.1016/j.vaccine.2015.07.069.
- Tamura K, Chang B, Shimbashi R, et al. Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013-2019. Vaccine. 2022;40(24):3338–3344. doi: 10.1016/j.vaccine.2022.04.062.
- Sando E, Suzuki M, Furumoto A, et al. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: the Japan pneumococcal vaccine effectiveness study (J-PAVE). Vaccine. 2019;37(20):2687–2693. doi: 10.1016/j.vaccine.2019.04.009.
- Akata K, Chang B, Yatera K, et al. Distribution and annual changes in Streptococcus pneumoniae serotypes in adult japanese patients with pneumonia. J Infect Chemother. 2015;21(10):723–728. doi: 10.1016/j.jiac.2015.07.002.
- Ubukata K, Chiba N, Hanada S, et al. Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010-2013. Emerg Infect Dis. 2015;21(11):1956–1965. doi: 10.3201/eid2111.142029.
- Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113. doi: 10.1371/journal.pone.0177113.
- Pilishvili T. 13-valent pneumococcal conjugate vaccine (PCV13) effects on disease caused by serotype 3. CDC; 2019. [cited 2022 May 31]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2019-02-508.pdf.
- Yanagihara K, Kosai K, Mikamo H, et al. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan. Int J Infect Dis. 2021;102:260–268. doi: 10.1016/j.ijid.2020.10.017.
- Furuya Y, Yamagishi Y, Okade H, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution of adult non-invasive Streptococcus pneumoniae isolates in tokai region, Japan, 2008-2016. J Infect Chemother. 2017;23(6):394–399. doi: 10.1016/j.jiac.2017.03.014.
- Food and Drug Administration. Label for pneumococcal 15-valent conjugate vaccine. 2023 [cited 2023 Apr 6]. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/1158fa93-ef41-4a29-8252-9251f94c53c8/spl-doc?hl=Pneumococcal%2015-valent%20Conjugate%20Vaccine.
- European Medicines Agency. Label for pneumococcal 15-valent conjugate vaccine. 2022 [cited 2023 Apr 6]. Available from: https://www.ema.europa.eu/en/documents/product-information/vaxneuvance-epar-product-information_en.pdf.
- An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations. 2023 [cited 2023 Jun 29]. Available from: https://www.canada.ca/content/dam/hc-sc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-interim-guidance-pneumococcal-15-valent-conjugate-vaccine-pneu-c-15-pediatric-populations/national-advisory-committee-immunization-interim-guidance-pneumococcal-15-valent-conjugate-vaccine-pneu-c-15-pediatric-populations.pdf.
- Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent pneumococcal conjugate vaccine among U.S. Children: updated recommendations of the advisory committee on immunization practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–117. doi: 10.15585/mmwr.mm7104a1.
- Pharmaceuticals and Medical Devices Agency. Label for pneumococcal 15-valent conjugate vaccine. 2023 [cited 2023 Aug 8]. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/631140K. Japanese.
- Annual Surveillance Data. Epidemiological Status in FY2020. 2023 [cited 2023 Jan 19]. Available from: https://ipd-information.com/?page_id=58.
- Greenberg D, Hoover PA, Vesikari T, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018;36(45):6883–6891. doi: 10.1016/j.vaccine.2018.02.113.
- Lupinacci R, Rupp R, Wittawatmongkol O, et al. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine. 2023;41(5):1142–1152. doi: 10.1016/j.vaccine.2022.12.054.
- Merck & Co., Inc., Rahway, NJ, USA. U.S. FDA approves merck’s VAXNEUVANCE™ (pneumococcal 15-valent conjugate vaccine) for the prevention of invasive pneumococcal disease in infants and children [Internet]. 2022. [cited 2023 Mar 7]. Available from: https://www.merck.com/news/u-s-fda-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-and-children/.
- Huang M, Hu T, Weaver J, et al. Cost-Effectiveness analysis of routine use of 15-Valent pneumococcal conjugate vaccine in the US pediatric population. Vaccines (Basel). 2023;11(1):135. doi: 10.3390/vaccines11010135.
- Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(5):317–328. doi: 10.1016/S1473-3099(10)70048-7.
- Center for Outcomes Research and Economic Evaluation for Health. National institute of public health (C2H). Guideline for preparing cost-effectiveness evaluation to the central social insurance medical council: Core2 health; 2022 [cited 2023 Mar 7]. Available from: https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf.
- Ministry of Health, Labour and Welfare. The patient survey. [cited 2023 Jan 19]. Available from: https://www.e-stat.go.jp/stat-search/files?page=1&toukei=00450022&metadata=1&data=1. Japanese.
- Ministry of Health, Labour and Welfare. Overview of the 23rd life table (complete life table). 2023 [cited 2023 Mar 7]. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/life/23th/index.html. Japanese.
- National Institute of Infectious Disease. Notification Status of Invasive Pneumococcal Infection, 1st week 2014 ∼ 35th week. 2021 [cited 2023 Jan 19]. Available from: https://www.niid.go.jp/niid/ja/pneumococcal-m/pneumococcal-idwrs/10779-ipd-211126.html.
- National Institute of Infectious Disease. IASR 2023. 2023 [cited 2023 Jan 19]. Available from: https://www.niid.go.jp/niid/ja/pneumococcal-m/1372-idsc/iasr-topic/11763-515t.html.
- Chang B, Tamura K, Fujikura H, et al. Pneumococcal meningitis in adults in 2014-2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan. Sci Rep. 2022;12(1):3066. doi: 10.1038/s41598-022-06950-w.
- Fukusumi M, Chang B, Tanabe Y, et al. Invasive pneumococcal disease among adults in Japan, april 2013 to march 2015: disease characteristics and serotype distribution. BMC Infect Dis. 2017;17(1):2. doi: 10.1186/s12879-016-2113-y.
- Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in the aging japanese population: a multicenter prospective study. PLoS One. 2015;10(3):e0122247. doi: 10.1371/journal.pone.0122247.
- Okada T, Morozumi M, Sakata H, et al. A practical approach estimating etiologic agents using real-time PCR in pediatric inpatients with community-acquired pneumonia. J Infect Chemother. 2012;18(6):832–840. doi: 10.1007/s10156-012-0422-7.
- Otsuka T, Kitami O, Kondo K, et al. Incidence survey of acute otitis media in children in sado island, Japan–sado otitis media study (SADOMS). PLoS One. 2013;8(7):e68711. doi: 10.1371/journal.pone.0068711.
- Yamanaka N, Hotomi M, Sugita R. Disease-burden of acute otitis media on children and cost-effectiveness of pneumococcal conjugate vaccine in Japan. Jpn J Pediat. 2009;21(1):37–48.
- Suzuki K, Kurono Y, Ikeda K, et al. The seventh nationwide surveillance of six otorhinolaryngological infectious diseases and the antimicrobial susceptibility patterns of the isolated pathogens in Japan. J Infect Chemother. 2020;26(9):890–899. doi: 10.1016/j.jiac.2020.05.020.
- Nakano S, Fujisawa T, Ito Y, et al. Nationwide surveillance of paediatric invasive and non-invasive pneumococcal disease in Japan after the introduction of the 13-valent conjugated vaccine, 2015-2017. Vaccine. 2020;38(7):1818–1824. doi: 10.1016/j.vaccine.2019.12.022.
- Tashiro M, Fushimi K, Takazono T, et al. A mortality prediction rule for non-elderly patients with community-acquired pneumonia. BMC Pulm Med. 2016;16:39. doi: 10.1186/s12890-016-0199-z.
- Ministry of Health, Labour and Welfare. Number of routine vaccinations. 2023 [cited 2023 Mar 7]. Available from: https://www.mhlw.go.jp/topics/bcg/other/5.html. Japanese.
- Shiragami M, Mizukami A, Leeuwenkamp O, et al. Cost-Effectiveness evaluation of the 10-Valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine and 13-Valent pneumococcal vaccine in japanese children. Infect Dis Ther. 2014;4(1):93–112. doi: 10.1007/s40121-014-0053-7.
- Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495–1502. doi: 10.1016/S0140-6736(06)69637-2.
- Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4(5):399–406. doi: 10.1016/S2213-2600(16)00052-7.
- Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344(6):403–409. doi: 10.1056/NEJM200102083440602.
- Pichichero M, Kaur R, Scott DA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018;2(8):561–568. doi: 10.1016/S2352-4642(18)30168-8.
- Lewnard JA, Givon-Lavi N, Dagan R. Effectiveness of pneumococcal conjugate vaccines against community-acquired alveolar pneumonia attributable to vaccine-serotype Streptococcus pneumoniae among children. Clin Infect Dis. 2021;73(7):e1423–e1433. doi: 10.1093/cid/ciaa1860.
- Stoecker C, Hampton LM, Link-Gelles R, et al. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics. 2013;132(2):e324-32–e332. doi: 10.1542/peds.2012-3350.
- Treskova M, Scholz SM, Kuhlmann A. Cost effectiveness of elderly pneumococcal vaccination in presence of Higher-Valent pneumococcal conjugate childhood vaccination: systematic literature review with focus on methods and assumptions. Pharmacoeconomics. 2019;37(9):1093–1127. doi: 10.1007/s40273-019-00805-5.
- Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193–1202. doi: 10.1016/j.jval.2021.03.010.
- Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634–7643. doi: 10.1016/j.vaccine.2010.09.049.
- Mangen M-JJ, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in The Netherlands. Eur Respir J. 2015;46(5):1407–1416. doi: 10.1183/13993003.00325-2015.
- Glick HA, Miyazaki T, Hirano K, et al. One-Year quality of life Post-Pneumonia diagnosis in japanese adults. Clin Infect Dis. 2021;73(2):283–290. doi: 10.1093/cid/ciaa595.
- Deloitte. Summary of medical reimbursement revisions, 2022. 2023 [cited 2023 Jan 19]. Available from: https://www2.deloitte.com/jp/ja/pages/life-sciences-and-healthcare/articles/hc/hc-hoshu-kaitei.html. Japanese.
- Ministry of Health, Labour and Welfare. Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein] suspension for intramuscular injection. 2023 [cited 2023 Mar 3]. Available from: https://www.mhlw.go.jp/stf/shingi/2r985200000371fc-att/2r985200000371td.pdf. Japanese.
- Ministry of Health, Labour and Welfare. Guidelines for evaluating the cost-effectiveness of vaccination. 2023 [cited 2023 Mar 3]. Available from: https://www.mhlw.go.jp/stf/shingi/2r98520000014ryv-att/2r98520000014sdi.pdf. Japanese.
- Hoshi SL, Kondo M, Okubo I. Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan. Vaccine. 2013;31(25):2762–2771. doi: 10.1016/j.vaccine.2013.03.052.
- Ministry of Health, Labour and Welfare. DPC NHI score list. 2023 [cited 2023 Jan 19]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000198757_00004.html. Japanese.
- Ministry of Health, Labour and Welfare. DPC statistics (In Japanese). 2023 [cited 2023 Jan 19]. Available from: https://www.mhlw.go.jp/stf/shingi2/0000196043_00005.html.
- Jiang Y, Yang X, Taniguchi K, et al. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan. J Med Econ. 2018;21(7):687–697. doi: 10.1080/13696998.2018.1465272.
- Konomura K, Nagai H, Akazawa M. Economic burden of community-acquired pneumonia among elderly patients: a japanese perspective. Pneumonia (Nathan). 2017;9:19. doi: 10.1186/s41479-017-0042-1.
- Ishiwada N, Iwata S, Sakata H, et al. Burden of illness of pneumonia caused by Streptococcus pneumoniae in children. Jpn J Pediat. 2008;61(11):2194–2204. Japanese.
- Iwata S, Ishiwada N, Sakata H, et al. Burden of illness of bacterial meningitis and bacteremia caused by Streptococcus pneumoniae in children. Jpn J Pediat. 2008;61(11):2206–2220. Japanese.
- Ministry of Health. Labour and welfare. Outline of basic survey on wage structure, 2020. 2021 [cited 2023 Mar 7]. Available from: https://www.mhlw.go.jp/english/database/db-l/schedule_releases.html. Japanese.
- Prasad N, Stoecker C, Xing W, et al. Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States. Vaccine. 2023;41(18):2914–2921. doi: 10.1016/j.vaccine.2023.03.045.
- Hoshi SL, Kondo M, Okubo I. Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan. Vaccine. 2012;30(22):3320–3328. doi: 10.1016/j.vaccine.2012.02.033.
- Rozenbaum MH, Sanders EA, van Hoek AJ, et al. Cost effectiveness of pneumococcal vaccination among dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340:c2509. doi: 10.1136/bmj.c2509.
- Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006;25(6):494–501. doi: 10.1097/01.inf.0000222403.42974.8b.
- McIntosh ED, Conway P, Willingham J, et al. Pneumococcal pneumonia in the UK–how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine. 2005;23(14):1739–1745. doi: 10.1016/j.vaccine.2004.08.051.
- Capra AM, Lieu TA, Black SB, et al. Costs of otitis media in a managed care population. Pediatr Infect Dis J. 2000;19(4):354–355. doi: 10.1097/00006454-200004000-00019.
- Cho BH, Stoecker C, Link-Gelles R, et al. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31(50):6011–6021. doi: 10.1016/j.vaccine.2013.10.024.
- Kobayashi M, Stoecker C, Xing W, et al. Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions. Hum Vaccin Immunother. 2021;17(7):2232–2240. doi: 10.1080/21645515.2020.1861876.
- Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. Jama. 2000;283(11):1460–1468. doi: 10.1001/jama.283.11.1460.
- Stoecker C, Kobayashi M, Matanock A, et al. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020;38(7):1770–1777. doi: 10.1016/j.vaccine.2019.12.029.